Debt-addicted cos turn towards selling equity as interest costs skyrocket

Late last year, the chief financial officer at Myriad Genetics Inc. took a different tack, one the DNA-testing company hadn't seriously considered in over 16 years - selling shares

from Latest News https://ift.tt/UW7vOzQ
via WebMD https://bsmedia.business-standard.com/_media/bs/img/article/2023-04/10/thumb/1681146330-9217.jpg